Sclerostin: A Potential Link between Osteoporosis and Alzheimer's Disease.

IF 1.9 4区 医学 Q3 CLINICAL NEUROLOGY
Ziyang Guo, Qian Xu, Kexin Zhang, Yujie Ma, Sufang Sheng, Dongqing Jing, Xiaodong Sun, Chengxia Kan, Xinjun Yu
{"title":"Sclerostin: A Potential Link between Osteoporosis and Alzheimer's Disease.","authors":"Ziyang Guo, Qian Xu, Kexin Zhang, Yujie Ma, Sufang Sheng, Dongqing Jing, Xiaodong Sun, Chengxia Kan, Xinjun Yu","doi":"10.1159/000547072","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoporosis and Alzheimer's disease (AD) are age-related health conditions that significantly impact patients and society. Sclerostin, a glycoprotein secreted by osteocytes, regulates bone metabolism by inhibiting the Wnt/β-catenin signaling pathway, which controls bone formation. Elevated sclerostin levels in osteoporosis contribute to increased bone resorption and reduced osteoblast activity. Recent studies suggest that sclerostin also affects the central nervous system, where its expression in brain tissues may impair synaptic function and accelerate cognitive decline in AD. Both osteoporosis and AD share common risk factors, such as aging, neuroinflammation, and oxidative stress, which exacerbate disease progression. Targeting sclerostin with therapies like Romosozumab, a monoclonal antibody that inhibits sclerostin activity, has shown promise in treating osteoporosis by promoting bone formation. Given the potential connection between sclerostin and AD, there is growing interest in exploring sclerostin modulation as a therapeutic strategy for AD, though challenges such as crossing the blood-brain barrier remain. This review discusses the emerging relationship between osteoporosis and AD, emphasizing the shared molecular pathways and the potential for sclerostin-targeted therapies to benefit both conditions. Further research is needed to understand the causal links between sclerostin, osteoporosis, and AD, and to assess the effectiveness of sclerostin modulation in managing both diseases simultaneously.</p>","PeriodicalId":19115,"journal":{"name":"Neurodegenerative Diseases","volume":" ","pages":"1-17"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547072","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoporosis and Alzheimer's disease (AD) are age-related health conditions that significantly impact patients and society. Sclerostin, a glycoprotein secreted by osteocytes, regulates bone metabolism by inhibiting the Wnt/β-catenin signaling pathway, which controls bone formation. Elevated sclerostin levels in osteoporosis contribute to increased bone resorption and reduced osteoblast activity. Recent studies suggest that sclerostin also affects the central nervous system, where its expression in brain tissues may impair synaptic function and accelerate cognitive decline in AD. Both osteoporosis and AD share common risk factors, such as aging, neuroinflammation, and oxidative stress, which exacerbate disease progression. Targeting sclerostin with therapies like Romosozumab, a monoclonal antibody that inhibits sclerostin activity, has shown promise in treating osteoporosis by promoting bone formation. Given the potential connection between sclerostin and AD, there is growing interest in exploring sclerostin modulation as a therapeutic strategy for AD, though challenges such as crossing the blood-brain barrier remain. This review discusses the emerging relationship between osteoporosis and AD, emphasizing the shared molecular pathways and the potential for sclerostin-targeted therapies to benefit both conditions. Further research is needed to understand the causal links between sclerostin, osteoporosis, and AD, and to assess the effectiveness of sclerostin modulation in managing both diseases simultaneously.

骨质疏松症和阿尔茨海默病之间的潜在联系。
骨质疏松症和阿尔茨海默病(AD)是与年龄相关的健康状况,对患者和社会产生重大影响。硬化蛋白是一种由骨细胞分泌的糖蛋白,通过抑制Wnt/β-catenin信号通路来调节骨代谢,而Wnt/β-catenin信号通路控制骨形成。骨质疏松症中硬化蛋白水平升高有助于骨吸收增加和成骨细胞活性降低。最近的研究表明,硬化蛋白也影响中枢神经系统,其在脑组织中的表达可能损害突触功能,加速AD患者的认知能力下降。骨质疏松症和AD都有共同的危险因素,如衰老、神经炎症和氧化应激,这些因素会加剧疾病的进展。用Romosozumab(一种抑制硬化蛋白活性的单克隆抗体)等疗法靶向硬化蛋白,有望通过促进骨质形成来治疗骨质疏松症。鉴于硬化蛋白和AD之间的潜在联系,人们对探索硬化蛋白调节作为AD的治疗策略越来越感兴趣,尽管仍然存在穿越血脑屏障等挑战。这篇综述讨论了骨质疏松症和AD之间的新关系,强调了共享的分子途径和硬化蛋白靶向治疗的潜力,以使这两种疾病受益。需要进一步的研究来了解硬化蛋白、骨质疏松症和AD之间的因果关系,并评估硬化蛋白调节在同时控制这两种疾病中的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurodegenerative Diseases
Neurodegenerative Diseases 医学-临床神经学
CiteScore
5.90
自引率
0.00%
发文量
14
审稿时长
6-12 weeks
期刊介绍: ''Neurodegenerative Diseases'' is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer''s disease, Parkinson''s disease, amyotrophic lateral sclerosis, Huntington''s disease and related neurological and psychiatric disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信